NKTR NEKTAR THERAPEUTICS
Pharmaceutical Preparations · Nasdaq · SEC CIK 906709 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-16.6%
TTM net income YoY-46.8%
TTM EPS YoY18.0%
Revenue 3-yr CAGR-16.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-319.8%
Net margin-339.7%
FCF margin-493.4%
EBITDA margin-318.5%
Returns
ROE-37.9%
ROA-26.5%
ROIC (approx.)-30.7%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets18.1%
Debt / equity0.00x
Current ratio9.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.45x
Accruals ratio11.9%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $55.23M | $98.43M | $90.12M | $92.06M | $101.91M |
| Cost of revenue | $0 | $30.69M | $33.77M | $21.64M | $24.90M |
| Gross profit | $55.23M | $67.74M | $56.35M | $70.42M | $77.01M |
| R&D expense | $117.33M | $120.91M | $114.16M | $218.32M | $400.27M |
| SG&A expense | $68.67M | $76.75M | $77.42M | $92.33M | $122.84M |
| Operating income | -$140.10M | -$105.20M | -$263.68M | -$376.17M | -$446.10M |
| Interest expense | — | — | — | $0 | $0 |
| Pretax income | -$164.21M | -$119.20M | -$276.26M | -$364.98M | -$523.28M |
| Income tax | -$138,000 | -$239,000 | -$200,000 | $3.21M | $557,000 |
| Net income | -$164.08M | -$118.96M | -$276.06M | -$368.20M | -$523.84M |
| EBITDA | -$139.08M | -$100.81M | -$256.68M | -$363.97M | -$433.10M |
| EPS (basic) | -9.73 | -8.68 | -1.45 | -1.97 | -2.86 |
| EPS (diluted) | -9.73 | -8.68 | -1.45 | -1.97 | -2.86 |
| Weighted avg. shares (diluted) | 16.87M | 13.71M | 190.00M | 187.14M | 183.30M |
| Balance sheet | |||||
| Cash & equivalents | $15.12M | $44.25M | $35.28M | $88.23M | $25.22M |
| Short-term investments | $230.64M | $210.97M | $268.34M | $416.75M | $708.74M |
| Receivables | — | $0 | $1.21M | $5.98M | $22.49M |
| Inventory | $0 | $0 | $16.10M | $19.20M | $15.80M |
| Current assets | $266.27M | $261.29M | $330.70M | $545.97M | $795.58M |
| PP&E, net | $2.06M | $3.41M | $18.86M | $32.45M | $60.51M |
| Goodwill | — | — | $0 | $76.50M | $76.50M |
| Total assets | $280.41M | $303.85M | $398.03M | $710.60M | $1.12B |
| Current liabilities | $53.54M | $61.40M | $51.27M | $68.20M | $85.20M |
| Total liabilities | $190.57M | $243.11M | $267.05M | $343.96M | $437.68M |
| Shareholders' equity | $89.83M | $60.74M | $130.99M | $366.64M | $679.51M |
| Shares outstanding | 20.38M | 12.39M | 191.38M | 188.56M | 185.47M |
| Cash flow statement | |||||
| Operating cash flow | -$208.51M | -$175.71M | -$192.61M | -$304.01M | -$412.66M |
| Capital expenditure | $171,000 | $1.47M | $865,000 | $5.68M | $14.99M |
| Free cash flow | -$208.68M | -$177.18M | -$193.47M | -$309.68M | -$427.65M |
| Investing cash flow | -$1.20M | $142.57M | $139.56M | $365.83M | $202.78M |
| Financing cash flow | $180.57M | $42.12M | $30,000 | $1.51M | $36.24M |
| Depreciation & amortization | $1.03M | $4.39M | $7.00M | $12.20M | $13.00M |
| Stock-based compensation | $12.65M | $21.61M | $33.39M | $57.32M | $94.67M |
| Share buybacks | $0 | $3.00M | $0 | — | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.